Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Israeli naval intelligence reduces Iranian threat to Strait of Hormuz - 2Chinese astronauts’ return to Earth delayed over fears spaceship damaged by debris
- 3Solar storms have influenced our history – an environmental historian explains how they could also threaten our future
- 4‘Inoculation’ helps people spot political deepfakes, study finds
- 5Vote in favor of the Web-based Work out schedule to Keep You Fit and Sound
- Indoor Drinking Fountains: Famous Home Advancements during the Pandemic
- Federal judge upholds Hawaii's new climate change tax on cruise passengers
- 2025 Was Another Exceptionally Hot Year
- Heading to Florida for NASA's Artemis 2 moon launch? Here's what to know before you go
- It's your last chance to subscribe to Paramount+ before they raise their prices: Here's how to lock in current pricing
- Find Successful Magnificence Items for Sparkling Skin
- Figuring out the Business venture Code: The Response to Building an Effective Startup
- This star-forming galaxy is blowing out powerful winds topping 2 million mph
- Ageless Tastefulness: An Outline of Valuable Gemstones and Adornments
